EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

详细信息	查看全文 | 推荐本文 |

• 作者：Jean-Charles Soria^a ; ^{jean-charles.soria@igr.fr} ; Tony S. Mok^b ; ^e ; ^{tony@clo.cuhk.edu.hk} ; Federico Cappuzzo^c ; ^f ; ^{f.cappuzzo@googlemail.com} ; Pasi A. Jä ; nne^d ; ^g ; ^{Pasi_Janne@dfci.harvard.edu}
• 关键词：Biological markers ; Carcinoma ; Non-small cell lung ; Receptor ; Epidermal growth factor ; Erlotinib ; Gefitinib ; Mutation ; Oncogenes
• 刊名：Cancer Treatment Reviews
• 出版年：2012
• 期刊代码：44_03057372
• 类别：med
• 出版时间：August, 2012
• 卷：38
• 期：5
• 页码：416-430
• 文件大小：516 K

摘要

Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase have been termed 鈥榦ncogene addicted鈥?to reflect their dependence on EGFR-mediated pro-survival signalling and their high susceptibility to apoptosis induced by EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g. gefitinib and erlotinib). The most common mutations (L858R and exon 19 deletions) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum-based chemotherapy in patients with advanced NSCLC. Moreover, these mutations are also prognostic of a relatively indolent course of disease, regardless of treatment, as compared with classical NSCLC. Treatment strategies for oncogene-addicted NSCLC are therefore distinct from those for non-oncogene addicted NSCLC, and will depend on the specific genetic mutation present.